TG Therapeutics, Inc.

TG is a biopharmaceutical company focused on the development of novel treatments for B-cell diseases.

Founded 2011

New York, United States 384 employees Post-IPO Debt Biotechnology, Health Care +1

Founded in 2011, TG Therapeutics, Inc. is a prominent player in the biopharmaceutical industry, with a primary focus on developing innovative treatments for B-cell diseases. The company's slogan, "TG is a biopharmaceutical company focused on the development of novel treatments for B-cell diseases," reflects its core mission. TG Therapeutics has an extensive research pipeline that encompasses several investigational medicines. One of its notable accomplishments is the completion of a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody designed to target a unique epitope on CD20-expressing B-cells. This innovative approach aims to treat patients with relapsing forms of multiple sclerosis (RMS). TG Therapeutics primarily operates within the biotechnology, health care, and health and wellness sectors, positioning itself at the intersection of cutting-edge medical research and market potential. Based in the United States, the company stands at the forefront of developing therapies that address critical unmet medical needs. As of now, there is no publicly disclosed information regarding the latest investment or the associated investors for TG Therapeutics, Inc. However, given the innovative nature of its research and the potential impact of its treatments, the company may attract interest and support from venture capital firms and investors looking to back pioneering advancements in the biopharmaceutical space.

FAQ About TG Therapeutics, Inc.

TG is a biopharmaceutical company focused on the development of novel treatments for B-cell diseases.

TG Therapeutics, Inc. was founded in 2011.

TG Therapeutics, Inc. is headquartered in New York, United States.

TG Therapeutics, Inc. operates in Biotechnology, Health Care and Health and Wellness.

TG Therapeutics, Inc. has approximately 384 employees.

Top alternatives and competitors to TG Therapeutics, Inc. include Arsanis, Onena Medicines, Rewind Therapeutics, NeuroGenesis Bio Inc., Vigil Neuroscience. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

TG Therapeutics, Inc. and Arsanis are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About TG Therapeutics, Inc.

TG Therapeutics, Inc. Alternatives & Competitors

FAQ About TG Therapeutics, Inc.